Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 55

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Pipeline Review, H1 2018

Summary

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) pipeline Target constitutes close to 8 molecules. The latest report Ileal SodiumBile Acid Cotransporter - Pipeline Review, H1 2018, outlays comprehensive information on the Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Ileal Sodium/Bile Acid Co-transporter is encoded by SLC10A2 gene. It plays a critical role in the sodium-dependent reabsorption of bile acids from the lumen of the small intestine and cholesterol metabolism. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1 and 3 respectively. Report covers products from therapy areas Gastrointestinal, Dermatology, Genetic Disorders and Metabolic Disorders which include indications Non-Alcoholic Steatohepatitis (NASH), Cholestasis, Primary Sclerosing Cholangitis, Alagille Syndrome, Primary Biliary Cirrhosis, Progressive Familial Intrahepatic Cholestasis, Pruritus, Biliary Atresia, Liver Diseases and Type 2 Diabetes.

Furthermore, this report also reviews key players involved in Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2)

- The report reviews Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics and enlists all their major and minor projects

- The report assesses Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Overview
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Companies Involved in Therapeutics Development
Albireo Pharma Inc
CJ HealthCare Corp
GlaxoSmithKline Plc
Shire Plc
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Drug Profiles
A-4250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-14199 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit IBAT for Liver and Metabolic Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elobixibat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2330672 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
maralixibat chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-435 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
volixibat potassium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Dormant Products
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Discontinued Products
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Product Development Milestones
Featured News & Press Releases
May 28, 2018: PIII Clinical Study Data on Chronic Constipation Treatment "GOOFICE 5mg Tablet" Will Be Presented at DDW2018
May 16, 2018: Albireo Enrolls First Patient in Phase 3 PFIC Trial of A4250
Apr 19, 2018: World's First Bile Acid Transporter Inhibitor GOOFICE 5mg Tablet Launched in Japan
Apr 19, 2018: Albireo to Present Data from Two Studies on Cholestatic Liver Disease at the 51st ESPGHAN Annual Meeting
Apr 14, 2018: Albireo Reports Data on Pharmacodynamic Marker for A4250 in Children with Cholestatic Liver Disease at the International Liver Congress 2018
Mar 28, 2018: Albireo to Present Clinical Data on A4250 at The International Liver Congress 2018
Jan 19, 2018: New drug approval of bile acid transporter inhibitor "GOOFICE 5mg Tablet "for chronic constipation was obtained in Japan
Oct 20, 2017: Final Results of Albireo's Phase 2 Study of A4250 in Children with Cholestatic Liver Disease Presented at The Liver Meeting 2017
Oct 03, 2017: Final Results of Albireos Phase 2 Study of A4250 in Children with Cholestatic Liver Disease to be Presented at The Liver Meeting 2017
Sep 26, 2017: EMA's Pediatric Committee Agrees to Albireo's A4250 Pediatric Investigation Plan
May 18, 2017: Albireo Announces Plans for Phase 3 Clinical Program of A4250 in Patients with PFIC
May 16, 2017: Albireo Announces Two New U.S. Patents Allowed for A4250 with Term into 2031
Apr 27, 2017: Albireo Announces Elobixibat Data from Japan to be Presented at DDW 2017
Apr 22, 2017: Promising Pediatric Data for Albireo's A4250 to be Presented at The International Liver Congress 2017
Apr 05, 2017: EASL Selects Albireo's A4250 Data for Late Breaker Presentation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Albireo Pharma Inc, H1 2018
Pipeline by CJ HealthCare Corp, H1 2018
Pipeline by GlaxoSmithKline Plc, H1 2018
Pipeline by Shire Plc, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
  • Global Addiction Treatment Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Oct-2018        Price: US 3480 Onwards        Pages: 135
    Drug addiction is a chronic, recurrent disease characterized by the uncontrolled application of an addictive drug. In recent years, the abuse of exogenous opioids (such as morphine and heroin) has become a serious social problem. It does not care about the physical and mental health of the abuser himself. It also has disastrous consequences for families and society. Opioid withdrawal is extremely difficult once it is abused. Scope of the Report: This report focuses ......
  • Global Turmeric Capsules Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Oct-2018        Price: US 3480 Onwards        Pages: 137
    The aromatic root of the turmeric plant has been used for centuries as a treatment for digestive disorders, inflammation, arthritis and infection. Many of turmeric's historic uses are not necessarily supported by scientific evidence. Nevertheless, turmeric supplements are commonly prescribed as a component of modern integrative medicine. early studies suggest that turmeric can promote the health of your joints, blood vessels and digestive tract. Compounds in turmeric capsules may also offer hope......
  • Global Alpha 1 Antitrypsin Deficiency Treatment Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Oct-2018        Price: US 3480 Onwards        Pages: 150
    Severe deficiency of alpha-1 antitrypsin (AAT) can cause early-onset emphysema and several liver diseases, including cirrhosis, neonatal hepatitis and hepatocellular carcinoma. Scope of the Report: This report focuses on the Alpha 1 Antitrypsin Deficiency Treatment in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.......
  • Global Alpha Mannosidosis Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Oct-2018        Price: US 3480 Onwards        Pages: 113
    Alpha-mannosidosis is a lifelong multi-systemic progressive disease, with neuromuscular and skeletal deterioration over decades. Scope of the Report: This report focuses on the Alpha Mannosidosis in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. There is no cure for congenital alpha-mannosidosis, and in......
  • Global Ambulatory Surgical & Emergency Center Services Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Oct-2018        Price: US 3480 Onwards        Pages: 128
    The Modern Ambulatory Surgical & Emergency Center Services has developed into a large-scale emergency medical technology center and emergency medical science research center integrating treatment and rescue, medical referral, technical guidance and emergency treatment, emergency and intensive care, and can be used for emergency, critical, and critical patients. The implementation of one-stop emergency medical services without transfer was described as the symbol of modern medicine and the patron......
  • Global Anesthesia Gas Blender Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Oct-2018        Price: US 3480 Onwards        Pages: 137
    The anesthesia machine is complex in structure and consists of a gas source, a gas mixing system, an anesthetic gas evaporator, a breathing circuit, a ventilator, an exhaust system, a monitoring system, an information management system, etc., and the user's safety, accuracy, reliability and Ease of use is higher. After more than half a century of development, the function of the anesthesia machine has basically not changed. The development of the gas supply system, the mechanical gas mixing syst......
  • Global Animal Blood Plasma Products and Derivatives Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Oct-2018        Price: US 3480 Onwards        Pages: 130
    Animal blood is one of the main by-products of animal slaughtering and processing. It has rich protein content and high nutritional value. Plasma protein, as an important protein material, can be used for animal feed and food processing. Studies have shown that plasma proteins are enzymatically treated to obtain hydrolysates consisting of small peptides and amino acids, which are more easily digested and absorbed by the body. At the same time, they show antioxidant properties, inhibition of angi......
  • Global Animal Health Care Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Oct-2018        Price: US 3480 Onwards        Pages: 135
    By 2050, the global population will expand to 9 billion - a two-thirds increase in future animal protein consumption. Population and income growth will bring about an increase in the consumption of animal protein. The growing demand for protein has given producers an opportunity to improve their production and profitability. Jianming's "all-round nutrition" solution meets two basic needs: providing healthy and safe nutrition solutions and maintaining good economic benefits. Scope ......
  • Global Anticancer Drugs Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Oct-2018        Price: US 3480 Onwards        Pages: 129
    Antineoplastic drugs, also known as anticancer drugs, anti-malignant drugs, refer to drugs for the treatment of malignant tumors. Scope of the Report: This report focuses on the Anticancer Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Simply put, there are chemotherapy drugs and biological age......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs